ViroPharma (VPHM +3.4%) trades higher after releasing its 2013 outlook this morning. The company says it expects net product sales to be between $450M to $475M. Analysts are looking for around $467M. The numbers are encouraging, because Cinryze has become key to the drug developer's future as the it's former blockbuster antibiotic Vancocin is expected to see sales hurt by the potential entry of generic rivals going forward.
ViroPharma (VPHM +3.4%) trades higher after releasing its 2013 outlook this morning. The company...
From other sites
at CNBC.com (Jun 8, 2015)
at CNBC.com (May 21, 2015)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 15, 2015)
at CNBC.com (Jan 13, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs